2-((4-bromopyridin-2-yl)(methyl)amino)ethan-1-ol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-((4-bromopyridin-2-yl)(methyl)amino)ethan-1-ol
• 英文别名: 2-[(4-Bromopyridin-2-yl)-methylamino]ethanol；2-[(4-bromopyridin-2-yl)-methylamino]ethanol
• 化学式: C₈H₁₁BrN₂O
• 分子量: 231.092
• InChiKey: DIUGITLEUSMBTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((4-bromopyridin-2-yl)(methyl)amino)ethan-1-ol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(2’-((2-hydroxyethyl)(methyl)amino)-[3,4′-bipyridin]-6-yl)-2-(3-methoxyphenyl)acetamide
  参考文献：
  名称：

  Discovery of bipyridine amide derivatives targeting pRXRα-PLK1 interaction for anticancer therapy

  摘要：

  DOI：

  10.1016/j.ejmech.2023.115341
• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 、 4-溴-2-氟吡啶 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以85.6 %的产率得到2-((4-bromopyridin-2-yl)(methyl)amino)ethan-1-ol
  参考文献：
  名称：

  新型 4,4'-联吡啶衍生物的设计、合成和生物学评价，作为针对三阴性乳腺癌的 CDK9-Cyclin T1 蛋白-蛋白相互作用抑制剂

  摘要：

  细胞周期蛋白依赖性激酶 9 (CDK9) 与三阴性乳腺癌 (TNBC) 患者的肿瘤发展直接相关。CDK9 增加与患者预后不良显着相关，而抑制 CDK9-Cyclin T1 蛋白-蛋白相互作用最近已被证明是 TNBC 治疗的新方法。在此，我们合成了一类新型 4,4'-联吡啶衍生物，作为针对 TNBC 的潜在 CDK9-Cyclin T1 PPI 抑制剂。所代表的化合物B19被发现是一种优异的选择性 CDK9-Cyclin T1 PPI 抑制剂，对 TNBC 细胞系具有良好的效力，同时在正常人细胞系中表现出比阳性化合物 I- CDK9更低的毒性。值得注意的是，化合物B19在治疗指数超过 42 的小鼠中表现出良好的药代动力学特性和优异的抗 TNBC (4T1) 同种异体移植物活性 (TGI 4T1 (12.5 mg/kg, i . p .)  = 63.1% vs. LD 50  = 537 毫

  DOI：

  10.1016/j.ejmech.2023.115858

文献信息

• [EN] C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉ INHIBITEUR DE TYROSINE KINASE C-ABL, MODES DE RÉALISATION, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：US HEALTH

  公开号：WO2019173761A1

  公开（公告）日：2019-09-12

  Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c- Abl inhibitory compound embodiments.

  本文披露了一种抑制c-Abl酪氨酸激酶（本文中也称为"c-Abl"）的化合物实施例。本文描述的这些化合物实施例是新颖的c-Abl抑制剂，可以结合到c-Abl的一个变构位点，并在各种途径中抑制其活性。这些化合物实施例还能够穿过血脑屏障，因此在抑制影响大脑途径和/或蛋白质的c-Abl活性方面是有用的。本文描述的这些化合物实施例是治疗涉及c-Abl的疾病的有效治疗剂，如癌症、运动神经元疾病和神经退行性疾病。本文还披露了制备和使用c-Abl抑制化合物实施例的方法实施例。
• Design, synthesis, and biological evaluation of novel 4,4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer
  作者：Guiping Gao、Jiayi Li、Yin Cao、Xudan Li、Yuqing Qian、Xiumei Wang、Mengyu Li、Yingkun Qiu、Tong Wu、Liqiang Wang、Meijuan Fang

  DOI：10.1016/j.ejmech.2023.115858

  日期：2023.12

  poor patient prognosis, while inhibiting CDK9-Cyclin T1 protein-protein interaction has recently been demonstrated as a new approach to TNBC treatment. Herein, we synthesized a novel class of 4,4′-bipyridine derivatives as potential CDK9-Cyclin T1 PPI inhibitors against TNBC. The represented compound B19 was found to be an excellent and selective CDK9-Cyclin T1 PPI inhibitor with good potency against TNBC

  细胞周期蛋白依赖性激酶 9 (CDK9) 与三阴性乳腺癌 (TNBC) 患者的肿瘤发展直接相关。CDK9 增加与患者预后不良显着相关，而抑制 CDK9-Cyclin T1 蛋白-蛋白相互作用最近已被证明是 TNBC 治疗的新方法。在此，我们合成了一类新型 4,4'-联吡啶衍生物，作为针对 TNBC 的潜在 CDK9-Cyclin T1 PPI 抑制剂。所代表的化合物B19被发现是一种优异的选择性 CDK9-Cyclin T1 PPI 抑制剂，对 TNBC 细胞系具有良好的效力，同时在正常人细胞系中表现出比阳性化合物 I- CDK9更低的毒性。值得注意的是，化合物B19在治疗指数超过 42 的小鼠中表现出良好的药代动力学特性和优异的抗 TNBC (4T1) 同种异体移植物活性 (TGI 4T1 (12.5 mg/kg, i . p .)  = 63.1% vs. LD 50  = 537 毫
• C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME
  申请人：The USA, as represented by the Secretary, Dept. of Health and Human Services

  公开号：US20210101872A1

  公开（公告）日：2021-04-08

  Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.
• [EN] COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]VIVACE THERAPEUTICS, INC.

  公开号：WO2023146512A1

  公开（公告）日：2023-08-03

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
• Discovery of bipyridine amide derivatives targeting pRXRα-PLK1 interaction for anticancer therapy
  作者：Jun Chen、Taige Zhao、Fengming He、Yijing Zhong、Susu Wang、Ziqing Tang、Yingkun Qiu、Zhen Wu、Meijuan Fang

  DOI：10.1016/j.ejmech.2023.115341

  日期：2023.6